Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data
10:45am, Thursday, 16'th May 2024
Data from the study shows that nearly half of the patients who received Roche's (RHHBY) subcutaneously-administered obesity drug lost more than 20% of their body weight after 24 weeks.
Roche says weight loss drug shows promising results in early trial
09:54am, Thursday, 16'th May 2024
The weekly injection helped patients with obesity lose 18.8% of their weight relative to those who received a placebo, after 24 weeks in the phase one trial.
Roche ramps up obesity-drug competition with early-stage trial results
08:41am, Thursday, 16'th May 2024
The race to develop powerful new weight-loss drugs grew even more heated on Thursday as Roche Holding AG released early-stage trial results for an experimental obesity treatment.
Roche shares gain on obesity drug results from early-stage trial
03:30am, Thursday, 16'th May 2024
Roche shares gained 4.7% at the market open on Thursday after an early-stage trial showed that the obesity drug candidate by newly acquired Carmot Therapeutics led to significant weight loss.
Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity
01:10am, Thursday, 16'th May 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase Ib clinical trial of CT-388, a dual G
Basel, 16 May 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase I clinical trial of CT-388, a dual GLP-1/GIP receptor agonist being developed for the treatment
Roche says FDA approves HPV self-test in US
01:11am, Wednesday, 15'th May 2024
Swiss drugmaker Roche on Wednesday said the US Food and Drug Administration (FDA) has approved its human papillomavirus (HPV) self-testing kit.
Basel, 15 May 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the FDA approval of its human papillomavirus (HPV) self-collection solution, one of the first available in the United States. Sc
Bank of Japan has 'put a floor under the yen,' but it is not on 'firm footing,' David Roche says
09:30pm, Monday, 13'th May 2024
David Roche, president and global strategist at Independent Strategy, discusses the Bank of Japan's monetary policy and the Japanese yen.
David Roche: The Japanese aren't aiming for a particularly strong yen
03:00am, Thursday, 09'th May 2024
David Roche, president and global strategist at Independent Strategy, says they're aiming for a "relatively stable" yen.
Roche: Value Remains Despite Covid-19 Revenue Growth Loss
05:44am, Sunday, 28'th Apr 2024
Vabysmo and Phesgo are still strong growth drivers for the company going forward, growing year over year in Q1 of 2024 by 108% and 70%, respectively. Mid-single digit sales growth is expected to remai
SAN DIEGO--(BUSINESS WIRE)--Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision thera
Roche Holding AG (RHHBY) Q1 2024 Sales/Trading Statement Call Transcript
04:16pm, Wednesday, 24'th Apr 2024
Roche Holding AG (OTCQX:RHHBY) Q1 2024 Sales/ Trading Statement Conference Call April 24, 2024 8:00 AM ET Company Participants Thomas Schinecker - Chief Executive Officer, Roche Group Alan Hippe - Chi
Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales
10:16am, Wednesday, 24'th Apr 2024
Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.
Roche prepares for business after boom from COVID-related products
06:51am, Wednesday, 24'th Apr 2024
Swiss pharmaceutical giant Roche on Wednesday said falling sales of COVID-19 tests and medicines will stop having a “material impact” on its business after the first quarter of 2024 following the
